Virginia Castilla Llorente
Chief Scientific Officer CamMed Therapeutics Ltd
Seminars
Wednesday 27th May 2026
RNARISE™: A Compact, Non-Viral Self-Amplifying RNA Platform for Therapeutics
1:30 pm
- Leverage AI-driven discovery to identify novel eukaryotic RNA replicases and engineer a 1.8 kb non-viral self-amplifying system
- Demonstrate biochemical validation and cell data confirming functional RNA amplification
- Translate platform innovation toward therapeutic application through early protein replacement programs in MPSIIIA/B
Tuesday 26th May 2026
Engineering Immunogenicity & Dosing Strategies to Enable Redosing & Expand Therapeutic Reach
Repeat-dose RNA therapeutics require careful engineering to reduce innate activation, expand the therapeutic window and support multi-dose regimens. This workshop provides a clear framework for understanding immunogenicity drivers, designing for tolerability and aligning dosing strategies with long-term clinical needs.
This workshop will gather experts to discuss:
- Reduce reactogenicity and strengthen safety margins by pinpointing innate immune activation pathways and integrating immunology, delivery, and regulatory considerations early in development
- Strategies to improve the potency of saRNA to drive lowered dosing and maximize the therapeutic window
- Differentiate the role of RNA design versus formulation and delivery in maximizing potency, durability, and dose efficiency
- Enable multi-cycle regimens by structuring redose-ready delivery and dosing strategies across diverse tissues and indications
This workshop is for:
Teams developing therapeutic RNA programs who need to overcome dose ceilings and enable safe, reliable redosing in autoimmune, oncology, neuromuscular or CNS applications
